Ginsenoside Rd: molecular mechanisms, pharmacological activities, and therapeutic potential

Area of Science:

• Pharmacology and Natural Product Chemistry
• Molecular Biology and Disease Mechanisms
• Translational Medicine and Drug Development

Background:

• Ginsenoside Rd (Rd), a saponin from Panax species, exhibits pleiotropic effects relevant to ischemic, inflammatory, metabolic, and degenerative diseases.
• Extensive preclinical data demonstrate Rd's protective mechanisms, including modulation of oxidative stress, inflammation, mitochondrial function, and cell death pathways.
• Emerging research links Rd to ferroptosis, pyroptosis, barrier integrity, and immune modulation, expanding its therapeutic potential.

Purpose of the Study:

• To critically synthesize the evidence on Ginsenoside Rd (Rd) from its origin to disease-specific efficacy.
• To integrate existing and new data into a unified mechanistic framework for Rd's actions.
• To evaluate the translational readiness of Rd and propose a development strategy for clinical application.

Main Methods:

• Comprehensive review of literature on Rd's chemical properties, biotransformation, and molecular pharmacology.
• Analysis of preclinical (in vitro, in vivo) and early clinical study data across various disease models.
• Evaluation of pharmacokinetic, tolerability, and efficacy data, particularly from stroke trials.

Main Results:

• Rd modulates interconnected pathways (PI3K/Akt, ERK, NF-κB, Nrf2, NLRP3 inflammasome, AMPK/SIRT1) and regulates cell death processes.
• Intravenous Rd demonstrated favorable pharmacokinetics and tolerability in humans; stroke trials indicated functional benefits.
• Challenges to translation include low oral bioavailability, variable metabolism, and inconsistent experimental designs.

Conclusions:

• Ginsenoside Rd (Rd) is a promising natural product scaffold with broad therapeutic potential, supported by extensive preclinical evidence.
• Clinical translation requires addressing bioavailability issues, optimizing delivery (e.g., IV administration), and employing rigorous standardization.
• A precision-oriented development strategy focusing on exposure optimization, biomarker stratification, and tailored trial design is essential for realizing Rd's clinical value.